Limula SA is a Life Science start-up based in Lausanne, Switzerland. Limula was established with the explicit mission to help bring the most personalised treatments to patients in need, at reasonable cost, wherever they are. Limula provides a proprietary platform that performs all steps of CAR T-cell manufacturing in a sequence and in a single device, using end-to-end automation and integrated process analytics. Our novel bioreactor design increases product quality and production capacity by reducing complexity, footprint, hands-on time and run cost. Our innovative solution supports the production of personalised cancer treatments on demand and at scale, directly at the point of care.